189 related articles for article (PubMed ID: 23179336)
21. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
[TBL] [Abstract][Full Text] [Related]
22. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.
Pant S; Saleh M; Bendell J; Infante JR; Jones S; Kurkjian CD; Moore KM; Kazakin J; Abbadessa G; Wang Y; Chen Y; Schwartz B; Camacho LH
Ann Oncol; 2014 Jul; 25(7):1416-1421. PubMed ID: 24737778
[TBL] [Abstract][Full Text] [Related]
23. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
Cleary JM; Lima CM; Hurwitz HI; Montero AJ; Franklin C; Yang J; Graham A; Busman T; Mabry M; Holen K; Shapiro GI; Uronis H
Invest New Drugs; 2014 Oct; 32(5):937-45. PubMed ID: 24916770
[TBL] [Abstract][Full Text] [Related]
24. A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus
Beatty GL; Shahda S; Beck T; Uppal N; Cohen SJ; Donehower R; Gabayan AE; Assad A; Switzky J; Zhen H; Von Hoff DD
Oncologist; 2019 Jan; 24(1):14-e10. PubMed ID: 30115734
[TBL] [Abstract][Full Text] [Related]
25. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Rajan A; Carter CA; Kelly RJ; Gutierrez M; Kummar S; Szabo E; Yancey MA; Ji J; Mannargudi B; Woo S; Spencer S; Figg WD; Giaccone G
Clin Cancer Res; 2012 Apr; 18(8):2344-51. PubMed ID: 22371451
[TBL] [Abstract][Full Text] [Related]
26. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC
Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
[TBL] [Abstract][Full Text] [Related]
28. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
[TBL] [Abstract][Full Text] [Related]
29. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors.
Huie M; Carducci M; Liu G; Wilding G; Marnocha R; Izquierda M; Thomas J
Am J Clin Oncol; 2005 Dec; 28(6):613-7. PubMed ID: 16317274
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Bendell J; O'Reilly EM; Middleton MR; Chau I; Hochster H; Fielding A; Burke W; Burris H
Ann Oncol; 2015 Apr; 26(4):804-811. PubMed ID: 25573533
[TBL] [Abstract][Full Text] [Related]
32. Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial.
Tassinari D; Drudi G; Panzini I; Pasini G; Arcangeli V; Fochessati F; Gianni L; Mianulli AM; Oliverio G; Pasquini E; Sartori S; Ravaioli A
Int J Clin Oncol; 2001 Dec; 6(6):279-83. PubMed ID: 11828946
[TBL] [Abstract][Full Text] [Related]
33. Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors.
Subbiah V; Grilley-Olson JE; Combest AJ; Sharma N; Tran RH; Bobe I; Osada A; Takahashi K; Balkissoon J; Camp A; Masada A; Reitsma DJ; Bazhenova LA
Clin Cancer Res; 2018 Jan; 24(1):43-51. PubMed ID: 29030354
[No Abstract] [Full Text] [Related]
34. Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.
Dudek AZ; Larson T; Keshtgarpour M; Kumar P
Am J Clin Oncol; 2007 Oct; 30(5):481-6. PubMed ID: 17921707
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
[TBL] [Abstract][Full Text] [Related]
36. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Rademaker-Lakhai JM; Beerepoot LV; Mehra N; Radema SA; van Maanen R; Vermaat JS; Witteveen EO; Visseren-Grul CM; Musib L; Enas N; van Hal G; Beijnen JH; Schellens JH; Voest EE
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4474-81. PubMed ID: 17671132
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
Saraiya B; Chugh R; Karantza V; Mehnert J; Moss RA; Savkina N; Stein MN; Baker LH; Chenevert T; Poplin EA
Invest New Drugs; 2012 Feb; 30(1):258-65. PubMed ID: 20697775
[TBL] [Abstract][Full Text] [Related]
38. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
[TBL] [Abstract][Full Text] [Related]
39. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Schilsky RL; Bertucci D; Vogelzang NJ; Kindler HL; Ratain MJ
J Clin Oncol; 2002 Jan; 20(2):582-7. PubMed ID: 11786589
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
Galatin PS; Advani RH; Fisher GA; Francisco B; Julian T; Losa R; Sierra MI; Sikic BI
Invest New Drugs; 2011 Oct; 29(5):971-7. PubMed ID: 20349264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
